671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase,(CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective …
Background MRSA infections, especially involving the endovascular system (eg, IE), are
associated with unacceptably high morbidity and mortality rates. The use of bacteriophage …
associated with unacceptably high morbidity and mortality rates. The use of bacteriophage …
1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin …
D Huang, E Gaukel, K Borroto-Esoda… - Open Forum …, 2021 - ncbi.nlm.nih.gov
Background Anti-staphylococcal phage lysins, such as LSVT-1701, represent important
candidate adjunctive agents against invasive MRSA infections because of both their …
candidate adjunctive agents against invasive MRSA infections because of both their …
Efficacy of antistaphylococcal lysin LSVT-1701 in combination with daptomycin in experimental left-sided infective endocarditis due to methicillin-resistant …
DB Huang, E Gaukel, N Kerzee… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
We utilized the rabbit model of aortic valve infective endocarditis to examine the combined
efficacy of the lysin LSVT-1701 plus daptomycin. The combination of LSVT-1701 plus …
efficacy of the lysin LSVT-1701 plus daptomycin. The combination of LSVT-1701 plus …
Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies
Objectives A failure to daptomycin therapy and subsequent emergence of a daptomycin non-
susceptible isolate occurred during the 1990 clinical investigation of daptomycin for the …
susceptible isolate occurred during the 1990 clinical investigation of daptomycin for the …
1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
RE Mendes, J Lindley, N Gurung… - Open Forum …, 2021 - academic.oup.com
Abstract Background Exebacase (CF-301) is a lysin (peptidoglycan hydrolase enzyme) with
anti-staphylococcal activity. CF-301 is in Phase 3 of clinical development for the treatment of …
anti-staphylococcal activity. CF-301 is in Phase 3 of clinical development for the treatment of …
Effect of the lysin exebacase on cardiac vegetation progression in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis as determined by …
SU Shah, YQ Xiong, W Abdelhady, J Iwaz… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
Methicillin-resistant Staphylococcus aureus (MRSA) poses significant therapeutic
challenges related to its frequency in clinical infections, innate virulence properties, and …
challenges related to its frequency in clinical infections, innate virulence properties, and …
1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus (S. aureus) …
P Ghahramani, T Khariton, J Chiu… - Open Forum Infectious …, 2020 - ncbi.nlm.nih.gov
Background Exebacase, a novel, antibacterial direct lytic agent for the treatment of S. aureus
bacterimia and endocarditis, studied in Phase 1 and 2 trials, demonstrated potential to …
bacterimia and endocarditis, studied in Phase 1 and 2 trials, demonstrated potential to …
614. Metabolic Interventions for the Resensitization of Daptomycin-Resistant (DAP-R) Streptococcus mitis-oralis Strains to DAP In vitro and Ex Vivo in a Simulated …
Background Streptococcus mitis-oralis is a leading cause of IE. Treatment of this pathogen is
limited by frequent high-level β-lactam resistance and the propensity to develop high-level …
limited by frequent high-level β-lactam resistance and the propensity to develop high-level …
Synergistic activity of exebacase (CF-301) in addition to daptomycin against Staphylococcus aureus in a neutropenic murine thigh infection model
TE Asempa, K Abdelraouf, T Carabeo… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
We evaluated the efficacy of escalating doses of exebacase administered with
subtherapeutic daptomycin exposures against 8 Staphylococcus aureus isolates in a …
subtherapeutic daptomycin exposures against 8 Staphylococcus aureus isolates in a …
Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
R Cha, MJ Rybak - Diagnostic microbiology and infectious disease, 2003 - Elsevier
Daptomycin is a lipopeptide antibiotic that exhibits bactericidal activity against Gram-positive
bacteria. In pursuit of potential clinical dosing regimens for endocarditis, we evaluated two …
bacteria. In pursuit of potential clinical dosing regimens for endocarditis, we evaluated two …